Back to Search

JAMES CATTO, MD

MD

Surgery Physician

NPI: 1407944556Individual

Specialties, Licenses & Credentials

Surgery PhysicianPrimary

Surgery

Code: 208600000X

4301028302(MI)

Research & Publications (20)

Words of wisdom. Re: Sequence variant on 8q24 confers susceptibility to urinary bladder cancer.
PMID 19650218·Eur Urol·2009
8-other
Behavior of urothelial carcinoma with respect to anatomical location.
PMID 17437794·J Urol·2007
4-observational
The changing face of prostate cancer: can gains in epigenetic knowledge translate into improvements in clinical care?
PMID 17021907·J Mol Med (Berl)·2006
8-other
Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance.
PMID 16697867·J Urol·2006
8-other
Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.
PMID 16406976·J Urol·2006
8-other
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
PMID 15753461·J Clin Oncol·2005
8-other
Genetic instability and transitional cell carcinoma of the bladder.
PMID 14678361·BJU Int·2004
6-review
Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.
PMID 12712438·Int J Cancer·2003
8-other
Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
PMID 14519642·Clin Cancer Res·2003
8-other
FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
PMID 18584939·Eur Urol·2009
8-other
Predictive modeling in cancer: where systems biology meets the stock market.
PMID 19589024·Expert Rev Anticancer Ther·2009
8-other
Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
PMID 19336522·Clin Cancer Res·2009
4-observational
A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.
PMID 18325051·BJU Int·2008
4-observational
Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: in regard to Kotwal et al. (Int J Radiat Oncol Biol Phys 2008;70:456-463).
PMID 18640506·Int J Radiat Oncol Biol Phys·2008
8-other
Expression of beta-dystroglycan is reduced or absent in many human carcinomas.
PMID 18983465·Histopathology·2008
8-other
Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
PMID 18079051·Eur Urol·2008
4-observational
iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.
PMID 18232632·J Proteome Res·2008
8-other
More nomograms or better evidence of efficacy: what do we need in urologic oncology?
PMID 18262334·Eur Urol·2008
8-other
Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
PMID 17960617·Int J Cancer·2008
4-observational
Artificial intelligence and bladder cancer arrays.
PMID 18314629·Verh Dtsch Ges Pathol·2007
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3535 W 13 MILE RD, STE 205
ROYAL OAK, MI 48073

Location

Practice Location

3535 W 13 MILE RD, ROYAL OAK, MI
(248) 551-8180

Quick Facts

NPI
1407944556
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile